Gemcitabine plus carboplatin after progression on enfortumab vedotin and pembrolizumab for advanced urothelial cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, single-arm phase 2 trial using a two-stage design to measure response to gemcitabine plus carboplatin in adults with locally advanced or metastatic urothelial carcinoma previously treated with enfortumab vedotin and pembrolizumab. Patients receive gemcitabine 1000 mg/m2 on days 1 and 8 plus carboplatin AUC 5 on day 1 of a 21-day cycle until progression or unacceptable toxicity. Tumor response is assessed by RECIST v1.1 every 9 weeks, and the study includes interim futility analysis after 19 treated patients. Safety, survival, quality of life, and blood-based biomarkers including circulating tumor DNA will also be collected.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients must have metastatic or locally advanced histologically and radiographically confirmed urothelial carcinoma
* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v1.1
* Patients must have received treatment with enfortumab vedotin plus pembrolizumab in the first line setting. Study treatment may be started within 28 days of last treatment with EV-P or with continuing toxicities if considered by the Sponsor-Investigator to be safe and within the best interest of the patient.
* Age \> 18 years.
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Patients must have normal organ and marrow function as defined below.

  * Absolute neutrophil count \> 1,000/mm3 unless patient has constitutional neutropenia
  * Platelets \> 80,000/ul
  * Hemoglobin \> 8.0 g/dL
  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<2.5 x ULN or \<3.5 x upper limit of normal (ULN) if liver metastases
  * Creatinine Clearance \>20 mL/min
* Ability to understand and willingness to sign a written informed consent and HIPAA consent document
* Optional: Archival tumor biospecimen, when available, must be procured for correlative evaluation. If tumor tissue is not available or accessible despite good faith efforts, patient may still be treated on study. Formalin fixed paraffin embedded (FFPE) tissue block(s) or at least 15 unbaked, unstained slides are required. Tissue samples taken from a metastatic lesion prior to the start of screening are acceptable.

Exclusion Criteria:

* Patients who have had systemic treatment including EV-P or radiotherapy within 2 weeks prior to entering the study
* Patients who have had systemic treatment including EV-P or radiotherapy within 2 weeks prior to entering the study
* Patients who have received more than one line of prior therapy or prior platinum-based chemotherapy for locally advanced or metastatic urothelial carcinoma (neoadjuvant platinum-based therapy including cisplatin is allowed)
* Patients who have not recovered from adverse events to less than Grade 2 secondary to agents administered more than 2 weeks prior to treatment initiation.
* Patients may not be receiving any other investigational agents
* Patients with uncontrolled and untreated CNS metastases:

  * Prior radiation to central nervous system (CNS) metastases is permitted
  * Prior history of CNS disease that has responded to previous systemic therapy is permitted only if no recurrence
  * Patient should not have leptomeningeal disease
  * CNS metastases have been clinically stable for at least 6 weeks prior to screening and baseline scans show no evidence of new or enlarged metastases
* Uncontrolled intercurrent illness including, but not limited to ongoing or active untreated infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit adherence with study requirements
* Subjects with a history of another invasive malignancy within 3 years before the first dose of study drug that cannot be watched and requires tumor- directed treatment, or any evidence of residual disease from a previously diagnosed malignancy that cannot be watched and requires treatment (adjuvant hormonal therapy for breast cancer is allowed)
* Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of first dose of chemotherapy (routine antimicrobial prophylaxis is permitted)
* Pregnant or breast feeding.

Where it's running

• Fox Chase Cancer Center
  Philadelphia, Pennsylvania, United States Recruiting
• Temple University Hospital at Broad Street
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Daniel Geynisman, MD — Fox Chase Cancer Center
• Study coordinator: Daniel Geynisman, MD
• Email: Daniel.Geynisman@fccc.edu
• Phone: (888) 369-2427

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Neoadjuvant enfortumab vedotin plus pembrolizumab for cisplatin-eligible upper tract urothelial cancer

  This trial tests whether giving enfortumab vedotin with pembrolizumab before surgery helps people with high-grade, cisplatin-eligible upper tract urothelial cancer.

  Recruiting at 2 sites Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan and 1 other locations · NCT06356155

• Peripheral neuropathy during perioperative therapy with enfortumab vedotin and pembrolizumab in muscle-invasive urothelial cancer

  This study follows adults with muscle-invasive urothelial cancer to see how nerve-related side effects develop when people receive enfortumab vedotin and pembrolizumab around surgery as part of standard care.

  Recruiting at 3 sites Comprehensive Cancer Center Munich (CCCM) · Munich, Bavaria and 2 other locations · NCT07870577

• Ivonescimab plus enfortumab vedotin vs pembrolizumab plus enfortumab vedotin in untreated locally advanced or metastatic urothelial cancer

  This trial tests if adding ivonescimab to enfortumab vedotin works better than pembrolizumab plus enfortumab vedotin for people with untreated locally advanced or metastatic urothelial cancer.

  Recruiting at 2 sites Phase 2/3 Summit Therapeutics · Phoenix, Arizona and 6 other locations · NCT07815665

• Enfortumab Vedotin, Pembrolizumab, and Quemliclustat for unresectable or metastatic urothelial cancer

  This trial tests a three-drug combination to see if it can safely treat unresectable or metastatic urothelial cancer in adults.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07667335

• Consolidative therapy after initial response in advanced bladder cancer

  This pilot trial tests adding radiation or surgery after a good response to EV + pembrolizumab in unresectable or oligometastatic muscle-invasive bladder cancer to see if residual disease can be eliminated or delayed from growing.

  Recruiting Phase 1/2 University of Washington · Seattle, Washington · NCT07579195

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.